Bris­tol My­ers Squibb spells out OS ben­e­fit of Op­di­vo/Yer­voy com­bo plus 'lim­it­ed' chemother­a­py — is it enough to change prac­tice?

Nor­mal­ly when a PD-1 in­hibitor is giv­en with chemother­a­py as a first-line treat­ment of non-small cell lung can­cer — a reg­i­men pop­u­lar­ized by Mer­ck and its mar­ket-lead­ing check­point drug Keytru­da — pa­tients go through four cy­cles of chemo, some­times more as main­te­nance. Bris­tol My­ers Squibb set out to test in CHECK­MATE-9LA whether two cy­cles plus a com­bi­na­tion of Op­di­vo and Yer­voy would do the job. At AS­CO, they will be mak­ing the case that it does.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.